Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Mexico for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Mexico only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Mexico (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sofia Palacio Cardenas (NPI 1063776086)

Field	Value
Entity Type	Individual
Organization	Sofia Palacio Cardenas
Address	4901 Lang Ave Ne
City	Albuquerque
State	NM
ZIP	87109
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 25, 2012

Payer Source	Total Paid
Medicare	$718.7K
Medicaid	$0

Key Findings

This provider’s Medicare business is heavily concentrated in high-cost oncology drug administration: J9271 (pembrolizumab) accounts for $421.4K in revenue and represents 59.4% of the provider’s Medicare receipts, and the precomputed top-3 Medicare codes account for 78.1% of total Medicare revenue. That concentration indicates the practice derives the majority of its Medicare revenue from a single immunotherapy agent and a small set of complementary services.

The service mix reflects an outpatient oncology infusion model combined with high-complexity office management. The presence of J9271 and J0897 (denosumab, $41K, 5.8% of Medicare revenue) alongside multiple chemotherapy administration codes (for example, 96413 at $24.9K, 3.5%) and supportive infusion items such as J1439 (ferric carboxymaltose, $27.8K, 3.9%) and J0881 (darbepoetin alfa, $20.6K, 2.9%) points to an operation that both dispenses high-cost biologic/immunotherapy drugs and provides attendant supportive care and chemotherapy services.

Revenue scale and payer mix are effectively single-payer: lifetime Medicare revenue is $718.7K and there is no Medicaid billing on file, so the provider is functionally Medicare-only in these datasets. The absence of Medicaid activity suggests the provider’s Medicare-derived reimbursement patterns and drug-administration revenue streams will dominate any analysis of volumes, margins, or network leverage.

Competitive standing varies by code: the provider is an extreme national outlier for office-based E/M complexity—99215 generated $91.1K and ranks #783 of 145531 providers nationally (99th percentile), indicating unusually high volume of high-complexity established-patient visits compared with peers. By contrast, the provider’s national position for pembrolizumab (J9271) is more modest: J9271 ranks #1206 of 1841 (34th percentile) and is described as "typical, unremarkable volume" for this drug, so the practice is not a dominant national supplier of that specific infusion despite J9271’s large share of its own revenue.

Several additional procedure and infusion codes show typical volumes rather than outlier status, which suggests a standard clinical throughput for chemotherapy and infusion services beyond the top revenue drivers. Examples include J0897 (rank #5603 of 10057, 43th percentile; typical, unremarkable volume), 96413 (rank #2244 of 7514, 70th percentile; typical, unremarkable volume), and 96401 (rank #2005 of 3868, 48th percentile; typical, unremarkable volume). This pattern is consistent with an oncology clinic that mixes one or two high-revenue biologics with routine chemotherapy and supportive treatments at modest volumes.

The provider’s billing profile shows meaningful dependence on high-complexity E/M visits as a secondary revenue stream: 99215 contributes $91.1K (12.9% of Medicare revenue) and appears to be unusually concentrated relative to national peers. That level of high-acuity office visit billing implies a patient panel requiring frequent, complex medical decision-making and may reflect longitudinal management of oncology patients in addition to infusion encounters.

Tenure of the provider’s enrollment is substantial: the NPI was enumerated on 2012-06-25 (~14 years ago), indicating the provider has an established billing history in Medicare. Combined with the current revenue mix, this tenure supports interpretation of these patterns as stable practice behaviors rather than a transient billing snapshot.

From a risk and contracting perspective, the combination of heavy revenue concentration in J9271 and no Medicaid volume creates sensitivity to changes in Medicare drug reimbursement, utilization management, or patient mix. With 59.4% of Medicare revenue tied to a single drug and no Medicaid billing to diversify payer exposure, payers and provider analysts should flag this profile for focused review when modeling drug reimbursement exposure, infusion capacity, or negotiation strategy.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

44 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	9,800	$40	$421.4K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	700	$130	$91.1K
J0897	Injection, denosumab, 1 mg	2,280	$20	$41K
J1439	Injection, ferric carboxymaltose, 1 mg	27,750	$1	$27.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	260	$100	$24.9K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	10,300	$1	$20.6K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	160	$120	$18.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	140	$90	$12.4K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	50	$160	$7.6K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	270	$20	$5.9K

Showing 1–10 of 44

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 44 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Mexico Distribution

Sofia Palacio Cardenas — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Mexico

Full comparison — all codes billed, vs. state median

44 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	6	10	9,400	$40	$469.6K
J0897	30	50	3,150	$20	$113.2K
J0881	5	10	12,320	$1	$31.2K
J9217	17	20	180	$130	$23.4K
J1439	5	10	25,500	$1	$23.1K
96413	10	40	170	$90	$17.7K
J3490	17	20	40	$150	$16.7K
99214	993	2,700	90	$70	$12.9K
99233	384	520	60	$90	$10.4K
99215	8	960	40	$110	$7.8K

Showing 1–10 of 44

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sofia Palacio Cardenas, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
New Mexico Oncology Hematology Consultants, Ltd.	NM	Hematology & Oncology Physician	$0	$4.2M
Gregg Franklin	NM	Radiation Oncology Physician	$2.5M	$0
Scott Stoerner	NM	Rheumatology Physician	$1.5M	$0
Shaya Ansari	NY	Diagnostic Radiology Physician	$1.5M	$1K
Pranshu Bansal	AZ	Hematology & Oncology Physician	$1.4M	$0
Ronald Kubica	NM	Medical Oncology Physician	$1M	$0
Annette Fontaine	NM	Medical Oncology Physician	$918.5K	$0
Mrunal Tailor	NM	Diagnostic Radiology Physician	$897.5K	$0
Jose Avitia	NM	Hematology & Oncology Physician	$880.2K	$0
Amyn Alidina	NM	Medical Oncology Physician	$785K	$0

Nearby Providers

Other providers in the same ZIP code as Sofia Palacio Cardenas, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Presbyterian Healthcare Services	NM	Internal Medicine Physician	$0	$240.8M
Heritage Home Healthcare Services, Inc.	NM	Home Health Agency	$0	$141.5M
Home Medical Equipment Specialists LLC	NM	Durable Medical Equipment & Medical Supplies	$0	$100M
The New Beginnings LLC	NM	Adult Day Care Clinic/Center	$0	$85.1M
We Care Agency, Inc.	NM	In Home Supportive Care Agency	$0	$60.1M
Lovelace Health System, LLC	NM	General Acute Care Hospital	$0	$57.7M
Adelante Development Center, Inc.	NM	Personal Care Attendant	$0	$57M
Eye Associates Of New Mexico Ltd	NM	Ophthalmology Physician	$0	$46.9M
Southwest Labs LLC	NM	Clinical Medical Laboratory	$1.1M	$41.5M
Southwest Medical Associates, LLC	NM	General Practice Physician	$0	$41.4M

Sofia Palacio Cardenas — Billing Profile & Reimbursement Data

Sign up for Sofia Palacio Cardenas — Billing Profile & Reimbursement Data policy alerts

Sofia Palacio Cardenas — Billing Profile & Reimbursement Data

Sign up for Sofia Palacio Cardenas — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References